Literature DB >> 28405079

Plasma cell myeloma with lymphoplasmacytic morphology and cyclin D1 expression, an uncommon variant.

Daniel A Hale1, John R Krause1.   

Abstract

The genetic complexity of multiple myeloma is due in part to the accumulation of mutations, with primary and secondary events. One such secondary event is the development of a gene mutation that may result in overexpression of cyclin D1. The pathway involving cyclin D1 is intricately involved in cell cycle regulation from the G1 to S phase, and alterations may contribute to tumorigenesis. We present a case of cyclin D1-positive multiple myeloma with lymphoplasmacytic morphology and discuss potential diagnostic pitfalls and effects on prognosis.

Entities:  

Year:  2017        PMID: 28405079      PMCID: PMC5349825          DOI: 10.1080/08998280.2017.11929581

Source DB:  PubMed          Journal:  Proc (Bayl Univ Med Cent)        ISSN: 0899-8280


  9 in total

1.  Immunohistochemical analysis identifies two cyclin D1+ subsets of plasma cell myeloma, each associated with favorable survival.

Authors:  James R Cook; Eric D Hsi; Sarah Worley; Raymond R Tubbs; Mohamad Hussein
Journal:  Am J Clin Pathol       Date:  2006-04       Impact factor: 2.493

2.  Plasma cell myeloma with lymphoplasmacytic morphology and cyclin D1 expression.

Authors:  Babita Kajal; Hong Chang
Journal:  Blood       Date:  2016-03-24       Impact factor: 22.113

3.  Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation.

Authors:  Simona Soverini; Michele Cavo; Claudia Cellini; Carolina Terragna; Elena Zamagni; Deborah Ruggeri; Nicoletta Testoni; Patrizia Tosi; Antonio De Vivo; Marilina Amabile; Tiziana Grafone; Emanuela Ottaviani; Barbara Giannini; Delia Cangini; Francesca Bonifazi; Antonino Neri; Sonia Fabris; Sante Tura; Michele Baccarani; Giovanni Martinelli
Journal:  Blood       Date:  2003-05-01       Impact factor: 22.113

4.  Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy.

Authors:  Philippe Moreau; Thierry Facon; Xavier Leleu; Nadine Morineau; Pauline Huyghe; Jean-Luc Harousseau; Régis Bataille; Hervé Avet-Loiseau
Journal:  Blood       Date:  2002-09-01       Impact factor: 22.113

5.  Cyclin D1 amplification in multiple myeloma is associated with multidrug resistance expression.

Authors:  Eman M Sewify; Ola A Afifi; Eman Mosad; Amen H Zaki; Sahar A El Gammal
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2014-01-25

6.  Alterations of the cyclin D1/pRb/p16(INK4A) pathway in multiple myeloma.

Authors:  A Krämer; B Schultheis; J Bergmann; A Willer; U Hegenbart; A D Ho; H Goldschmidt; R Hehlmann
Journal:  Leukemia       Date:  2002-09       Impact factor: 11.528

7.  MYD88 L265P mutation analysis helps define nodal lymphoplasmacytic lymphoma.

Authors:  Fatima Hamadeh; Stephen P MacNamara; Nadine S Aguilera; Steven H Swerdlow; James R Cook
Journal:  Mod Pathol       Date:  2014-09-12       Impact factor: 7.842

8.  Increased expression of cyclin-D1 on trephine bone marrow biopsies independently predicts for shorter overall survival in patients with multiple myeloma treated with novel agents.

Authors:  Anna Tasidou; Maria Roussou; Evangelos Terpos; Efstathios Kastritis; Maria Gkotzamanidou; Maria Gavriatopoulou; Magdalini Migkou; Evangelos Eleutherakis-Papaiakovou; Nikitas Nikitas; Dimitra Anagnostou; Meletios A Dimopoulos
Journal:  Am J Hematol       Date:  2012-05-06       Impact factor: 10.047

9.  Molecular analysis of 11q13 breakpoints in multiple myeloma.

Authors:  D Ronchetti; P Finelli; R Richelda; L Baldini; M Rocchi; L Viggiano; A Cuneo; S Bogni; S Fabris; L Lombardi; A T Maiolo; A Neri
Journal:  Blood       Date:  1999-02-15       Impact factor: 22.113

  9 in total
  1 in total

1.  Lymphoplasmacytic variant of multiple myeloma.

Authors:  Silje Johansen; Hilde Kollsete Gjelberg; Håkon Reikvam
Journal:  EJHaem       Date:  2022-04-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.